For each of the following hospitalized patients presenting with severe, confirmed, or highly suspected infections, select the most appropriate definitive or targeted empiric intravenous antimicrobial therapy from the options provided.
- A 62-year-old patient developing ventilator-associated pneumonia; endotracheal aspirate culture grows extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae.Intravenous meropenem
- A 54-year-old patient with a central line-associated bloodstream infection; blood cultures isolate vancomycin-resistant Enterococcus faecium.Intravenous daptomycin
- A 71-year-old patient with complicated pyelonephritis; urine and blood cultures grow Enterobacter cloacae demonstrating inducible AmpC beta-lactamase production.Intravenous cefepime
- A 48-year-old critically ill patient in the intensive care unit who develops new-onset septic shock and candidemia; fungal species identification is pending.Intravenous micafungin
Answer
The correct pairings match specific resistance mechanisms and pathogen profiles with their definitive antimicrobial therapy: ESBL Klebsiella with meropenem, VRE with daptomycin, AmpC Enterobacter with cefepime, and critically ill candidemia with micafungin.
Each clinical scenario requires a highly specific antimicrobial agent based on pathogen characteristics. Carbapenems (meropenem) are required for ESBL-producing organisms because they resist hydrolysis by these specific enzymes. Daptomycin is utilized for VRE because enterococci have inherent cephalosporin resistance, and VRE's altered peptidoglycan precursors render vancomycin ineffective. Cefepime avoids the induction of AmpC beta-lactamases seen in 'SPACE' organisms (like Enterobacter). Finally, echinocandins (micafungin) are the standard of care for empiric candidemia in the critically ill due to the high mortality associated with missing fluconazole-resistant strains.
Step-by-Step Solution
Key Concept
Selection of targeted antimicrobial therapy must account for specific molecular resistance mechanisms (e.g., ESBL, AmpC, VRE) and patient acuity (e.g., risk of azole-resistant Candida in the intensive care unit).